Search reports.
Orphan Drugs Market Size, Share, Growth & Forecast 2031
Get free sample report Request for Customiztion Buy Now

Orphan Drugs Market Size, Share, Growth & Forecast 2031

Segments - Orphan Drugs Market by Drug Types (Biological, and Non-Biological), Top Selling Drugs (Ninlaro, Imbruvica, Revlimid, Darzalex, Rituxan, Tafinlar, Myozyme, Soliris, Jakafi, Kyprolis, and Others), Disease Types (Oncology, Hematology, Neurology, Cardiovascular, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-3702 | 4.4 Rating | 76 Reviews | 219 Pages | Format : PDF Excel PPT

Report Description


The global orphan drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the advancements in genomic studies.

Global Orphan Drugs Market summary

Orphan drugs are treatments for uncommon diseases that have been developed with specific situations. Genetic problems cause the bulk of uncommon illnesses. Bacteria, viruses, and allergies are some of the ways that these diseases can impact an individual. Many nations have embraced the ODA Act, which has enhanced the production of orphan pharmaceuticals to treat diseases associated with it. This ODA policy included financial and non-financial factors to ensure easy orphan medication supply and access. The government agencies are granting tax credits and subsidies to patients and pharmaceutical businesses who are having a beneficial influence on the market as a result of this act.

  • Increasing demand for orphan pharmaceuticals is expected to drive the orphan drugs market expansion.
  • Rising knowledge of the availability and prevalence of various treatment procedures is propelling the market growth.
  • Growing number of people diagnosed with uncommon illnesses is anticipated to boost market growth.
  • Stringent rules and regulation by government for the approval of drugs development can hamper the market
  • Lack of awareness of the manufacturing process coupled with the latest technology is hindering the market.
  • Expanding trend of developing innovative treatments, as well as the expanding scale of health care institutions and pharmaceutical businesses, can create opportunities for the orphan pharmaceuticals industry.

Scope of the Report

The report on the global orphan drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Orphan Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Biological, and Non-biological), Top Selling Drugs ( Ninlaro, Imbruvica, Revlimid, Darzalex,  Rituxan, Tafinlar, Myozyme, Soliris, Jakafi, Kyprolis, and Others ), and Disease Types (Oncology, Hematology, Neurology, Cardiovascular, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Celgene Corporation; Novartis AG; F. Hoffmann-La Roche AG; Takeda Pharmaceutical Company Limited; and Johnson & Johnson

Orphan Drugs Market Segment Insights

Biological segment is expected to grow at a rapid pace

Based on types, the market is divided into biological, and non-biological. The biological segment is expected to grow at a rapid pace during the forecast period owing to increase in the number of uncommon diseases that can be treated using biological therapies. Furthermore, private firms are exploiting this segment's requirement by increasing their investments in the development of medications for rare illnesses. However, the non- biological segment is anticipated to hold a key share of the market in the coming years due to the increase in prevalence of genetic investigations and the rise in the number of patients suffering from chronic illnesses are accelerating segment's growth

Global Orphan Drugs Market types

Revlimid segment is projected to expand at a considerable CAGR

On the basis of top selling drugs, the market is segregated into ninlaro, imbruvica, revlimid, darzalex, rituxan, tafinlar, myozyme, soliris, jakafi, kyprolis, and others. The revlimid segment is projected to expand at a considerable CAGR during the forecast period due to increasing spending on revlimid due to rising prevalence of cancer.

Oncology segment is anticipated to account for a significant market share

Based on disease types, the market is divided into oncology, hematology, neurology, cardiovascular, and others. The oncology segment is estimated to account for a significant market share during the forecast period owing to a rise in the number of cancer patients. Additionally, pharmaceutical companies such as Johnson & Johnson, Abbvie, and Bristol-Myers Squibb are focusing on developing orphan medications for the cancer market. On the other hand, the neurology segment is anticipated to account for a major market share during the forecast period owing to growing incidence of neurological illnesses.

North America is anticipated to constitute a key market share

In terms of regions, the global orphan drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the projected period due to constant economic growth. Furthermore, the companies in North America ae adopting new technologies. However, the market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to increasing population, which is expanding the orphan drugs market share. Moreover, India and China are two of the most important countries in terms of market growth for Asia Pacific. The introduction of reimbursement systems in aforementioned countries is increasing market demand for orphan drugs.

Global Orphan Drugs Market region

Segments

Segments Covered in the Report
The global orphan drugs market has been segmented on the basis of
Types

  • Biological
  • Non-niological

Top Selling Drugs

  • Ninlaro
  • Imbruvica
  • Revlimid
  • Darzalex
  • Rituxan
  • Tafinlar
  • Myozyme
  • Soliris
  • Jakafi
  • Kyprolis
  • Others

Disease Types

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Celgene Corporation
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson

 

Competitive Landscape

Global orphan drugs are a moderately competitive market with a number of significant manufacturers such as Celgene Corporation; Novartis AG; F. Hoffmann-La Roche AG; Takeda Pharmaceutical Company Limited; and Johnson. In terms of market share, the market is currently dominated by a few significant competitors. With the increasing number of diseases and cases each year, a few smaller firms are entering the market and gaining a significant share of the industry.

Global Orphan Drugs Market keyplayers

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Orphan Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Orphan Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Orphan Drugs Market - Supply Chain
  4.5. Global Orphan Drugs Market Forecast
     4.5.1. Orphan Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Orphan Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Orphan Drugs Market Absolute $ Opportunity
5. Global Orphan Drugs Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Orphan Drugs Market Size and Volume Forecast by Types
     5.3.1. Biological
     5.3.2. Non-niological
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Orphan Drugs Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Orphan Drugs Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Orphan Drugs Demand Share Forecast, 2019-2026
7. North America Orphan Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Orphan Drugs Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Orphan Drugs Market Size and Volume Forecast by Types
     7.4.1. Biological
     7.4.2. Non-niological
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Orphan Drugs Demand Share Forecast, 2019-2026
8. Latin America Orphan Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Orphan Drugs Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Orphan Drugs Market Size and Volume Forecast by Types
     8.4.1. Biological
     8.4.2. Non-niological
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Orphan Drugs Demand Share Forecast, 2019-2026
9. Europe Orphan Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Orphan Drugs Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Orphan Drugs Market Size and Volume Forecast by Types
     9.4.1. Biological
     9.4.2. Non-niological
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Orphan Drugs Demand Share Forecast, 2019-2026
10. Asia Pacific Orphan Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Orphan Drugs Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Orphan Drugs Market Size and Volume Forecast by Types
     10.4.1. Biological
     10.4.2. Non-niological
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Orphan Drugs Demand Share Forecast, 2019-2026
11. Middle East & Africa Orphan Drugs Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Orphan Drugs Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Orphan Drugs Market Size and Volume Forecast by Types
     11.4.1. Biological
     11.4.2. Non-niological
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Orphan Drugs Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Orphan Drugs Market: Market Share Analysis
  12.2. Orphan Drugs Distributors and Customers
  12.3. Orphan Drugs Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Celgene Corporation
     12.4.2. Novartis AG
     12.4.3. F. Hoffmann-La Roche AG
     12.4.4. Takeda Pharmaceutical Company Limited
     12.4.5. Johnson & Johnson

Methodology

Our Clients

Nestle SA
Microsoft
General Mills
Deloitte
sinopec
Dassault Aviation
The John Holland Group
Pfizer